Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multidrug-resistant (MDR) bacterial infections.
Spero is committed to advancing innovative therapies for patients with rare diseases and serious MDR bacterial infections in both hospital and community settings. The company believes that embedding ESG considerations into its business strategies will not only drive sustained long-term value for its shareholders but also create a positive impact on the patients and communities it serves. As part of these considerations, the company is establishing and reviewing its policies with the aim of implementing new programs, if and when needed, to address pertinent ESG risks and opportunities, ensuring it maintains responsible and sustainable business practices.
Spero Therapeutics was founded in 2013 and went public on November 2, 2017.
Spero Therapeutics is listed on the NASDAQ Global Market with a ticker symbol of SPRO.
Spero Therapeutics is headquartered in Cambridge, MA.
You can find information about the Board of Directors and Leadership Team on our website, here.
We currently do not pay a dividend and do not offer a Dividend Reinvestment Plan.
84833T103.
You will need to open a brokerage account.
Please contact your broker if you own your shares through a broker, or if you beneficially own your shares, please contact our transfer agent.
Computershare is Spero's transfer agent.
Our legal counsel is Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Our independent auditor is PwC.
Spero Therapeutics is incorporated in Delaware, United States.
We do not yet have a comprehensive ESG reporting system. We recognize the importance of ESG and are actively working towards it.
You can reach out to investor relations at IR@sperotherapeutics.com.
To subscribe to Spero Therapeutics’ email list, sign up here.
All SEC filings can be found and downloaded here.
Spero Therapeutics is committed to advancing novel treatment approaches for rare diseases and MDR bacterial infections. Our experienced team of experts embrace the Latin word “spero,” which means “hope.” It is our mission to bring hope to patients and families of loved ones suffering from rare diseases and serious infections.
Spero Therapeutics is pursuing collaborations with partners for expertise and funding support.
Join our life-changing mission to deliver differentiated treatments to patients suffering with rare diseases and MDR bacterial infections. We seek individuals with unique talents who share our passion.
Have a question? Reach out to us!
